<html><head></head><body><h1>Lymphoseek</h1><p>Generic Name: technetium Tc 99m tilmanocept<br/>
Date of Approval: March 13, 2013<br/>
Company: Navidea Biopharmaceuticals, Inc.</p><p><strong>Treatment for: <i>Use in Lymphatic Mapping</i></strong></p><ul class="ddc-anchor-links"><li>FDA approval</li>
<li>Uses</li>
<li>Warnings</li>
<li>Side effects</li></ul><h2 class="ddc-anchor-offset" id="fda-approval">FDA Approves Lymphoseek</h2><p>The U.S. Food and Drug Administration (FDA) has approved Lymphoseek (technetium Tc 99m tilmanocept) Injection, a novel product indicated for use in lymphatic mapping procedures to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma. Lymphoseek is a receptor targeted radiopharmaceutical designed to identify these lymph nodes which have the highest probability of harboring cancer and thereby assist physicians in the staging of such patients.</p><h2 class="ddc-anchor-offset" id="uses">What is Lymphoseek?</h2><p>Lymphoseek (technetium Tc 99m tilmanocept) Injection is a novel, receptor-targeted, small-molecule radiopharmaceutical used in lymphatic mapping procedures that are performed to help stage breast cancer and melanoma. Lymphoseek is designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer, in patients with breast cancer or melanoma.</p><h2>What is Lymphoseek Used For?</h2><p>Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma.</p><h2 class="ddc-anchor-offset" id="warnings">Important Safety Information</h2><p>In clinical trials with Lymphoseek, no serious hypersensitivity reactions were reported, however Lymphoseek may pose a risk of such reactions due to its chemical similarity to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran drugs).</p><p>Prior to the administration of Lymphoseek, patients should be asked about previous hypersensitivity reactions to drugs, in particular dextran and modified forms of dextran. Resuscitation equipment and trained personnel should be available at the time of Lymphoseek administration, and patients observed for signs or symptoms of hypersensitivity following injection.</p><h2 class="ddc-anchor-offset" id="side-effects">Lymphoseek side effects</h2><p>The most common adverse reactions are injection site irritation and/or pain (&lt;1%).</p><h2>More about Lymphoseek (tilmanocept)</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>1 Review</li>
<li>Drug class: radiologic conjugating agents</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diagnosis and Investigation</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>